Literature DB >> 23365445

Oxysterol-binding protein family I is the target of minor enviroxime-like compounds.

Minetaro Arita1, Hirotatsu Kojima, Tetsuo Nagano, Takayoshi Okabe, Takaji Wakita, Hiroyuki Shimizu.   

Abstract

Enviroxime is an antipicornavirus compound that targets host phosphatidylinositol 4-kinase III beta (PI4KB) activity for its antipicornavirus activity. To date, several antipoliovirus (PV) compounds similar to enviroxime that are associated with a common resistance mutation in viral protein 3A (a G5318A [3A-Ala70Thr] mutation in PV) have been identified. Most of these compounds have a direct inhibitory effect on PI4KB activity, as well as enviroxime (designated major enviroxime-like compounds). However, one of the compounds, AN-12-H5, showed no inhibitory effect on PI4KB and was considered to belong to another group of enviroxime-like compounds (designated minor enviroxime-like compounds). In the present study, we performed a small interfering RNA (siRNA) sensitization assay targeting PI4KB-related genes and identified oxysterol-binding protein (OSBP) as a target of minor enviroxime-like compounds. Knockdown of OSBP and OSBP2 increased the anti-PV activities of AN-12-H5 and a newly identified minor enviroxime-like compound, T-00127-HEV2, and also to T-00127-HEV1 to a minor extent, in the cells. A ligand of OSBP, 25-hydroxycholesterol (25-HC), acted as a minor enviroxime-like compound. Minor enviroxime-like compounds induced relocalization of OSBP to the Golgi apparatus in cells. Treatment of the cells with major or minor enviroxime-like compounds suppressed the expression of genes (HMGCS1 and SQLE) in the SREBP/SCAP regulatory pathway and diminished endogenous phosphatidylinositol 4-phosphate (PI4P) at the Golgi apparatus. Our results suggested that minor enviroxime-like compounds are phenotypically identical to 25-HC and that major and minor enviroxime-like compounds suppress the production and/or accumulation of PI4P in PV-infected cells by targeting PI4KB and OSBP family I activities, respectively.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23365445      PMCID: PMC3624399          DOI: 10.1128/JVI.03546-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  Protein kinase D negatively regulates hepatitis C virus secretion through phosphorylation of oxysterol-binding protein and ceramide transfer protein.

Authors:  Yutaka Amako; Gulam H Syed; Aleem Siddiqui
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

2.  Characterization of poliovirus variants selected for resistance to the antiviral compound V-073.

Authors:  Hong-Mei Liu; Jason A Roberts; Deborah Moore; Barbara Anderson; Mark A Pallansch; Daniel C Pevear; Marc S Collett; M Steven Oberste
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

Review 3.  A case for developing antiviral drugs against polio.

Authors:  Marc S Collett; Johan Neyts; John F Modlin
Journal:  Antiviral Res       Date:  2008-05-13       Impact factor: 5.970

4.  ACBD3-mediated recruitment of PI4KB to picornavirus RNA replication sites.

Authors:  Jun Sasaki; Kumiko Ishikawa; Minetaro Arita; Koki Taniguchi
Journal:  EMBO J       Date:  2011-11-29       Impact factor: 11.598

5.  Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors.

Authors:  D C Pevear; M J Fancher; P J Felock; M G Rossmann; M S Miller; G Diana; A M Treasurywala; M A McKinlay; F J Dutko
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

6.  Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073.

Authors:  Diana V Kouiavskaia; Eugenia M Dragunsky; Hong-Mei Liu; M Steven Oberste; Marc S Collett; Konstantin M Chumakov
Journal:  Antivir Ther       Date:  2011

7.  Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives.

Authors:  H Shimizu; M Agoh; Y Agoh; H Yoshida; K Yoshii; T Yoneyama; A Hagiwara; T Miyamura
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

8.  Molecular pathogenesis of neural lesions induced by poliovirus type 1.

Authors:  T Couderc; C Christodoulou; H Kopecka; S Marsden; L F Taffs; R Crainic; F Horaud
Journal:  J Gen Virol       Date:  1989-11       Impact factor: 3.891

Review 9.  The OSBP-related proteins: a novel protein family involved in vesicle transport, cellular lipid metabolism, and cell signalling.

Authors:  Markku Lehto; Vesa M Olkkonen
Journal:  Biochim Biophys Acta       Date:  2003-02-20

10.  The thiazolobenzimidazole TBZE-029 inhibits enterovirus replication by targeting a short region immediately downstream from motif C in the nonstructural protein 2C.

Authors:  Armando M De Palma; Ward Heggermont; Kjerstin Lanke; Bruno Coutard; Mirko Bergmann; Anna-Maria Monforte; Bruno Canard; Erik De Clercq; Alba Chimirri; Gerhard Pürstinger; Jacques Rohayem; Frank van Kuppeveld; Johan Neyts
Journal:  J Virol       Date:  2008-03-12       Impact factor: 5.103

View more
  42 in total

Review 1.  Lipids and RNA virus replication.

Authors:  Kouacou V Konan; Lorena Sanchez-Felipe
Journal:  Curr Opin Virol       Date:  2014-09-28       Impact factor: 7.090

2.  Hepatitis C virus replication compartment formation: mechanism and drug target.

Authors:  Vineela Chukkapalli; Glenn Randall
Journal:  Gastroenterology       Date:  2014-03-25       Impact factor: 22.682

Review 3.  Rewiring of cellular membrane homeostasis by picornaviruses.

Authors:  George A Belov; Elizabeth Sztul
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

4.  Host lipidome analysis during rhinovirus replication in HBECs identifies potential therapeutic targets.

Authors:  An Nguyen; Anabel Guedán; Aurelie Mousnier; Dawid Swieboda; Qifeng Zhang; Dorottya Horkai; Nicolas Le Novere; Roberto Solari; Michael J O Wakelam
Journal:  J Lipid Res       Date:  2018-06-26       Impact factor: 5.922

5.  Model of OSBP-Mediated Cholesterol Supply to Aichi Virus RNA Replication Sites Involving Protein-Protein Interactions among Viral Proteins, ACBD3, OSBP, VAP-A/B, and SAC1.

Authors:  Kumiko Ishikawa-Sasaki; Shigeo Nagashima; Koki Taniguchi; Jun Sasaki
Journal:  J Virol       Date:  2018-03-28       Impact factor: 5.103

6.  A complex comprising phosphatidylinositol 4-kinase IIIβ, ACBD3, and Aichi virus proteins enhances phosphatidylinositol 4-phosphate synthesis and is critical for formation of the viral replication complex.

Authors:  Kumiko Ishikawa-Sasaki; Jun Sasaki; Koki Taniguchi
Journal:  J Virol       Date:  2014-03-26       Impact factor: 5.103

7.  Discovery of itraconazole with broad-spectrum in vitro antienterovirus activity that targets nonstructural protein 3A.

Authors:  Qianqian Gao; Shilin Yuan; Chao Zhang; Ying Wang; Yizhuo Wang; Guimei He; Shuyi Zhang; Ralf Altmeyer; Gang Zou
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

Review 8.  Immunometabolic Signaling Pathways Contribute to Macrophage and Dendritic Cell Function.

Authors:  Lucas T Jennelle; Aditya P Dandekar; Tshifhiwa Magoro; Young S Hahn
Journal:  Crit Rev Immunol       Date:  2016       Impact factor: 2.214

Review 9.  25-Hydroxycholesterols in innate and adaptive immunity.

Authors:  Jason G Cyster; Eric V Dang; Andrea Reboldi; Tangsheng Yi
Journal:  Nat Rev Immunol       Date:  2014-10-17       Impact factor: 53.106

10.  New small-molecule inhibitors effectively blocking picornavirus replication.

Authors:  Lauren A Ford Siltz; Ekaterina G Viktorova; Ben Zhang; Diana Kouiavskaia; Eugenia Dragunsky; Konstantin Chumakov; Lyle Isaacs; George A Belov
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.